There has been a recent seachange in the way that redox systems biology is viewed, with oxidative stress now being thought of not so much as a primary cause of disease but rather as a consequence of dysregulated signaling and impaired cellular function. This viewpoint has implications both for understanding the nature of redox events in signaling pathways and in pathophysiology, and for designing better therapeutics. In particular, the frequent failure in clinical trials of antioxidants may be rationalized by their inability to address primary defects in redox-based signaling. Fatigue of skeletal muscle, which is strongly linked to oxidative stress , is a common cause of weakness (and muscle damage) in respiratory disease, heart failure, congenital muscle disorders, and atrophic syndromes, including cachexia (muscle wasting), cancer, and aging. One immediate question is the nature of the cellular signal disrupted in fatigued skeletal muscle that results in oxidative stress. Answers to this question would shed light on the molecular basis of muscle injury and thus could suggest possible corrective measures.
Two recent papers-one by Durham et al. (2008) in this issue of Cell and another by Bellinger et al. (2008) in a recent issue of Proc. Natl. Acad. Sci. USA-now identify this cellular signal as nitric oxide (NO)-based. Viewed together, these studies suggest a continuum-from normal muscle contraction to muscle fatigue and malignant hyperthermia (MH)-that reflects the extent of modification of the ryanodine receptor calcium release channel (RyR1) by S-nitrosylation, ultimately resulting in leaky channels. Furthermore, mutations in RyR1 associated with MH (as well as a disorder called central core disease) are shown to increase the sensitivity of this calcium ion channel to NO, particularly at elevated temperatures. This observation provides support for the idea that hyper-S-nitrosylation of mutant RyR1 underlies the exercise-induced contractures and life-threatening muscle injury of exertional heat stroke (Durham et al., 2008; Wappler et al., 2001) . Sustained elevation of cytosolic calcium ions can raise respiratory activity of mitochondria and enhance their production of oxidants. Mitochondrial oxidative stress may therefore explain the injury to this organelle (swelling and formation of central cores) that may accompany congenital muscle disorders caused by RyR1 mutations, including MH, exertional heat stroke, and central core disease (Durham et al., 2008) . Collectively, these results suggest a common molecular basis for muscle disorders associated with dysregulated handling of calcium ions by RyR1, and may herald a new era for developing therapeutic approaches for treating oxidative and nitrosative stress.
In skeletal muscle, a splice variant of the neuronal isoform of nitric oxide synthase (nNOS) associates with the sarcolemmal dystrophin complex, and also localizes to the cytosol where (at least in heart muscle) it coimmunoprecipitates with the RyR channel (Kobzik et al., 1994; Gonzalez et al., 2007) . Although two other isoforms of NOS may be constitutively expressed in muscle and upregulated by exercise, nNOS is most clearly identified with contractile function. Notably, activity of skeletal muscle is coupled to nNOS expression, and mislocalization of nNOS occurs in muscular dystrophies, cachexia/atrophic syndromes, and heart failure. The two new studies suggest that RyR1 is a source of the calcium ions that activate nNOS (Durham et al., 2008) and that calcium-dependent upregulation of nNOS activity by either sustained exercise or RyR mutations leads to hyper-S-nitrosylation of RyR1 in mice and humans (Durham et al., 2008; Bellinger et al., 2008) .
Oxygen tension (pO 2 ) is low in resting muscle (?20 mm Hg) and falls with mild exercise. At physiological pO 2 , but not in room air, endogenous NO appears to activate RyR1 by S-nitrosylating one cysteine residue among ?50 free thiols in each RyR subunit (Figure 1 ). This cysteine (C3635) resides in a hydrophobic compartment within the calmodulin-binding domain of RyR1 (Eu et al., 2000; Sun et al., 2003) . Physiological activation of RyR1 by NO involves perturbation of a complex between calmodulin and RyR1. The requirement for physiological pO 2 entails an allosteric effect of a small set (six to Dysregulated S-nitrosylation of proteins characterizes a broad array of human disorders, but its role in disease etiology is not well understood. Two new studies (Durham et al., 2008; Bellinger et al., 2008) now show that hyper-S-nitrosylation of the ryanodine receptor calcium release channel (RyR1) in skeletal muscle disrupts calcium ion flux. This disruption underlies the impaired contractility and cellular damage of skeletal muscle during strenuous exercise and in a spectrum of congenital muscle disorders including malignant hyperthermia. eight) of additional RyR thiols whose redox state governs S-nitrosylation by NO. These pO 2 -responsive RyR thiols undergo oxidation in room air (probably by hydrogen peroxide generated by mitochondria or endogenous oxidases). Thus, under normal conditions, contractility of skeletal muscle reflects the precise regulation of S-nitrosylation (and its effects) by tissue pO 2 and calmodulin.
Another set of RyR thiols may serve as a redox sensor by coupling calciumion release to the ratio of cellular glutathione (GSH) to glutathione disulfide (GSSG). An additional set of RyR thiols may confer responsiveness to S-nitrosoglutathione (GSNO) (Sun et al., 2003; Aracena-Parks et al., 2006 and references therein). GSSG and GSNO activate the RyR channel by S-glutathionylation and S-nitrosylation, respectively. Unlike NO and GSSG, GSNO can inhibit the interaction of the protein FKBP12 with RyR1 (Bellinger et al., 2008 and references therein); displacement of FKBP12 destabilizes the channel, which becomes leaky. Thus, hydrogen peroxide, GSNO, and GSSG activate RyR1 through different cysteine-based modifications of different sets of thiols. The physiological or pathophysiological roles of these modifications have remained unclear.
Durham and colleagues studied mice carrying a mutation in RyR that causes MH in humans. They demonstrate that skeletal muscle from these mice exhibits hallmarks of both oxidative stress (decreased GSH/GSSG ratio, and increased S-glutathionylation of RyR) and nitrosative stress (increased S-nitrosylation of RyR). These results are reminiscent of dysregulated S-nitrosylation of RyR in cardiac muscle, which also leads to leaky channels and oxidative stress (Gonzalez et al., 2007) . Significantly, inhibition of NOS in the mutant mouse muscle restored the cellular GSH/GSSG balance, indicating that nitrosative stress mediates oxidative stress (Durham et al., 2008) . Because the amounts of NO derived from nNOS are much lower than cellular glutathione, increased nNOS activity presumably inhibits enzymes involved in glutathione synthesis or reduction. Treatment of mutant mice (A-C) Each subunit of the tetrameric ryanodine receptor calcium release channel (RyR1) within the sarcoplasmic reticulum of skeletal muscle possesses several discrete sets of cysteine thiols. These thiols are defined by differential susceptibility to modification by different endogenous redox active molecules: nitric oxide (NO), S-nitrosoglutathione (GSNO), glutathione disulfide (GSSG), and reactive oxygen species (ROS) such as hydrogen peroxide. The amounts and sources of these reactive molecules differ in resting muscle, after exercise, and with muscle injury. In (A), under normal conditions, neuronal nitric oxide synthase (nNOS) activates the RyR1 channel by S-nitrosylating up to one cysteine residue (Cys3635) per RyR subunit (four cysteines per RyR1 channel). S-nitrosylation (NO, light red) is coupled to muscle activity during moderate exercise through both increases in nNOS activity (increased cytosolic calcium ions) and a decline in tissue pO 2 that entails allosteric regulation of the RyR. In (B), with sustained exercise or in the presence of RyR mutations (e.g., in the disease malignant hyperthermia), increased calcium-ion release promotes aberrant S-nitrosylation (NO, dark red), which in turn results in dysregulated calcium ion flux. This feed-forward cycle is marked by hyper-S-nitrosylation of the RyR channel and leakage of calcium ions. Hyper-S-nitrosylation increases the temperature sensitivity of mutant RyR1 to activation and thus provides a molecular basis for the clinical syndromes of malignant hyperthermia and exertional heat stroke. In (C), nitrosative stress predisposes to oxidative stress. Formation of GSSG promotes Sglutathionylation (S-SG) of the RyR channel, which may accentuate leakage of calcium ions. Ultimately, mitochondria become activated (perhaps by a sustained elevation of calcium-ion levels), which increases their oxidative burden and the production of ROS, resulting in mitochondrial damage and its ramifications (e.g., central core disease). Further S-oxidation of RyR (S-O x ) is an inevitable consequence of mitochondrial and cellular injury. Thus, normal contractility, exercise, fatigue, malignant hyperthermia, exertional heat stroke, and central core disease may be viewed as a continuum from physiological S-nitrosylation to hyper-S-nitrosylation (nitrosative stress) and ultimately to oxidative injury of muscle.
with the thiol N-acetylcysteine (NAC), which restores the GSH/GSSG balance, lowered S-glutathionylation and S-nitrosylation of mutant RyR, but had no affect on basal S-nitrosylation. These data point to an equilibrium between S-nitrosylated RyR and GSNO that is disrupted during nitrosative stress, as well as to the sequestration of basal S-nitrosylated RyR in a solvent-inaccessible compartment characteristic of S-nitrosylated C3635 (Figure 1) . Although quantification and mapping of RyR S-nitrosylation will be needed to elucidate hyper-S-nitrosylation, strikingly, selective removal of the S-nitroso group by ascorbate normalized the temperature sensitivity of RyR from mice with the MH mutation.
A GSNO reductase (GSNOR) metabolizes GSNO thereby promoting de-Snitrosylation of proteins by glutathione (Figure 1 ). In contrast, solvent inaccessible S-nitrosylated proteins are subject to denitrosylation by as yet unidentified enzymes and are characteristically unresponsive to the acute effects of NOS inhibitors, as observed for RyR1 (Durham et al., 2008) . These results emphasize that aberrant S-nitrosylation of RyR1 may reflect dysregulated removal of NO groups. Bellinger et al. (2008) extend these observations into the physiological realm of exercise. They show that strenuous exercise in mice and humans is associated with gradual hyper-S-nitrosylation of RyR1 that is accompanied by depletion of FKBP12, resulting in leaky channels that impair exercise tolerance. Thus, there is overlap between the molecular signatures of extreme fatigue and of MH/exertional heat stroke. Selective de-S-nitrosylation of RyR channels, as reported by Durham et al. (2008) , may provide a mechanism for improving exercise capacity. Bellinger et al. (2008) also observed that muscle fatigue is accompanied by hyperphosphorylation of RyR1 mediated by protein kinase A (PKA), which results in displacement of FKBP12. Inhibitors of PKA-mediated phosphorylation may therefore protect against MH and exertional heat stroke. The effect of phosphorylation on the affinity of FKBP12 for RyR has been controversial. The new data now suggest that there may be allosteric coupling between S-nitrosylation and phosphorylation. Further attention to the redox state of RyR may help to resolve the controversy.
This new work suggests fresh therapeutic opportunities. Durham and coworkers show that NAC reverses hyper-S-nitrosylation of RyR channels and leakage of calcium ions in vitro, and that treatment for several months improves force generation in muscle and reverses mitochondrial injury in mice with the MH mutation. However, correction by NAC of the S-nitrosylation signaling defect in skeletal muscle may be counterbalanced by creation of another: conversion of NAC to S-nitroso-NAC in vivo depletes red blood cell S-nitrosohemoglobin and causes pulmonary hypertension (Palmer et al., 2007) . Perhaps the toxicity of chronic NAC therapy can be averted at lower doses or its effects replicated by muscle-specific alternatives. Inhibitors of nNOS, which prevent hyper-S-nitrosylation of RyR (Durham et al., 2008) , may also be useful in some instances. Bellinger and colleagues offer a complementary approach: a small molecule that stabilizes the interaction of FKBP12 with the hyper-Snitrosylated (or hyperphosphorylated) RyR channel, probably by stabilizing a channel conformation that favors binding of FKBP12. Remarkably, this molecule improved force generation and protected against muscle injury. A growing list of disorders are characterized by dysregulated S-nitrosylation, including Parkinson's disease, atrial fibrillation, sickle cell disease, pulmonary hypertension, cystic fibrosis, cancer, and heart failure. The new findings in skeletal muscle suggest that agents that modulate S-nitrosylation or its effects may represent a new class of therapeutics that could be of benefit in treating a broad spectrum of diseases.
